Search | Page 2 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents

    ... has been shown to yield red blood cell (RBC) transfusion independence in about 25% of lower risk myelodysplastic syndromes ...

    Research Article last updated 07/20/2018 - 5:14pm.

  2. Does addition of erythropoiesis stimulating agents improve the outcome of higher-risk myelodysplastic syndromes treated with azacitidine?

    ... patients reached HI-E (p=0.07); 48% and 20% achieved transfusion independence (p=0.01). Median OS was 19.6months in the ESA and 11.9months ...

    Research Article last updated 07/20/2018 - 5:14pm.

  3. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q

    ... the efficacy and safety of lenalidomide in 205 RBC transfusion-dependent patients with IPSS Low-/Intermediate-1-risk del5q31 ... 10- and 5-mg groups achieved RBC- transfusion independence (TI) for ≥ 26 weeks (primary endpoint) versus placebo (56.1% ...

    Research Article last updated 07/20/2018 - 5:14pm.

  4. Azacitidine in lower-risk myelodysplastic syndromes.

    ... 50% in lower-risk patients; most patients who achieved transfusion independence were also lower-risk. A further retrospective study reported ...

    Research Article last updated 07/20/2018 - 5:14pm.

  5. Lenalidomide for treatment of myelodysplastic syndromes: current status and future directions.

    ... the US Food and Drug Administration (FDA) for treatment of transfusion-dependent lower-risk myelodysplastic syndrome patients with ... was based on high rates of prolonged transfusion independence and complete cytogenetic response in this subset. In ...

    Research Article last updated 07/20/2018 - 5:14pm.

  6. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study

    ... RESULTS: Rates of red blood cell - transfusion independence (RBC-TI) ≥182 days were higher in the lenalidomide 10 mg ... benefits and acceptable safety profile of lenalidomide in transfusion-dependent patients with IPSS-defined Low-/Int-1-risk MDS with ...

    Research Article last updated 07/20/2018 - 5:15pm.

  7. Variations in erythropoiesis-stimulating agent administration in transfusion-dependent myelodysplastic syndromes impact response

    ... The study cohort consisted of patients with new-onset transfusion dependence (TD). All patients received an ESA at least once during ... for TD were met and continued until transfusion independence (TI). Kaplan-Meier statistics and Cox Proportional Hazard ...

    Research Article last updated 07/20/2018 - 5:15pm.

  8. Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C.

    ... haematological responses and increased red blood cell transfusion independence . Azacitidine prolonged overall survival versus LDara-C in ...

    Research Article last updated 07/20/2018 - 5:14pm.

  9. Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going

    ... clinical benefit. Anti-complement treatment allowed transfusion independence in at least half of PNH patients receiving eculizumab, with ...

    Research Article last updated 07/20/2018 - 5:15pm.

  10. Eltrombopag and improved hematopoiesis in refractory aplastic anemia

    ... were clinically significant changes in blood counts or transfusion independence . Patients with a response continued to receive eltrombopag. ...

    Research Article last updated 07/20/2018 - 5:14pm.